Plasma proteomic and metabolomic profiling reveals molecular features relevant to neoadjuvant therapy response in locally advanced esophageal squamous cell carcinoma.
A blood protein may predict who won't respond to immune-boosting cancer treatment, helping doctors adjust therapy earlier.
Longitudinal plasma multi-omics in ESCC identified DEFA1 as a validated negative predictor of pathological complete response after neoadjuvant immunochemotherapy, mechanistically linked to MDSC-mediated immune suppression. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective longitudinal cohort with independent validation (n=40 discovery, n=93 validation, n=33 mechanistic)
- Category
- precision_oncology
- Maturity
- Validated
- Journal
- Mol Cancer
Why it surfaced
Molecular Cancer publication with multi-cohort validation of DEFA1 as an actionable predictive biomarker and mechanistic target for overcoming immunotherapy resistance in ESCC.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.